The information on this page is not country-specific and may contain information that is outside the licensing conditions in your country. Please always refer to the prescribing information approved in your country.
Bonn Protocol Treatment Guidelines: The use of FEIBA during ITI
For more than 30 years, FEIBA has been a component of the Bonn ITI regimen.1,2
Dosing for FEIBA prophylaxis during ITI per Bonn protocol for patients with bleeding tendency*
- FVIII 100 IU/kg twice daily
- FEIBA 50 U/kg twice daily
- Discontinue FEIBA when inhibitor titre <1BU1**
*Bleeding tendency in the Bonn protocol is defined as more than six bleeds over six months.
**The local prescribing information may differ from these Bonn Protocol guidelines.
References
- 1. Gomperts ED, Astermark J, Gringeri A, Teitel J. From theory to practice: applying current clinical knowledge and treatment strategies to the care of hemophilia A patients with inhibitors. Blood Reviews 2008; 22(Suppl 1), S1-S11.
- 2. Brackmann HH, Oldenburg J, Schwaab R. Immune tolerance for the treatment of factor VIII inhibitors—twenty years' 'Bonn protocol'. Vox Sang. 1996;70(suppl 1):30-35.
Proven efficacy
Discover the efficacy of FEIBA in both on-demand and prophylaxis treatment. Read more
Dosing FEIBA
Learn how to dose FEIBA. Read more
Treatment challenges
Identify challenges in treating inhibitors and understand how to address them. Read more
This is an international site for FEIBA and is intended for Healthcare Providers outside the U.S. The information on this site is not country-specific and may contain information that is outside the licensing conditions in the specific country in which you live. Therefore, please always refer to the prescribing information approved in your country and use the product in line with the approved local prescribing information.